• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

儿童白消安剂量调整的回顾性评估

Retrospective appraisal of busulfan dose adjustment in children.

作者信息

Dupuis L L, Najdova M, Saunders E F

机构信息

Department of Pharmacy, The Hospital For Sick Children, Toronto, Ontario, Canada.

出版信息

Bone Marrow Transplant. 2000 Dec;26(11):1143-7. doi: 10.1038/sj.bmt.1702700.

DOI:10.1038/sj.bmt.1702700
PMID:11149723
Abstract

This report describes and critically appraises our experience with busulfan dose adjustment in children undergoing bone marrow transplant between April 1997 and March 1999. All children received an initial busulfan dose of 40 mg/m2 p.o. or by nasogastric tube. Whole blood samples were obtained 1, 1.5 and 6 h later and analyzed for busulfan content by gas chromatography with electron capture detection. The area under the whole blood busulfan concentration vs time curve (AUC) and an individualized dose which would achieve an AUC of 1300 microM/min were calculated. Mean and median busulfan doses were calculated using actual, ideal and effective body weight and stratified according to age. The relationship between the busulfan concentration at hour 6 and AUC was determined using linear regression. Thirty-nine courses of busulfan were evaluated in 38 patients. A change from the initial busulfan dose was required to achieve the target AUC in 34 courses (87%). Most children >1 to 5 years old required dose increments while most children >5 years old required dose reductions. Obesity did not significantly affect busulfan dose requirements. Busulfan concentrations at 6 h only weakly predicted the AUC achieved (r2 = 0.496; P = 0.001). Based on these findings, we recommend that the initial busulfan dose be assigned according to patient age and actual body weight. We also recommend that busulfan AUC be calculated for children using a four-sample (1, 1.5, 4 and 6 h) limited sampling technique.

摘要

本报告描述并批判性地评估了我们在1997年4月至1999年3月期间对接受骨髓移植的儿童进行白消安剂量调整的经验。所有儿童均接受初始口服或经鼻胃管给予的40mg/m²白消安剂量。在1小时、1.5小时和6小时后采集全血样本,并通过带有电子捕获检测的气相色谱法分析白消安含量。计算全血白消安浓度-时间曲线下面积(AUC)以及将达到1300μM/min的AUC所需的个体化剂量。使用实际体重、理想体重和有效体重计算白消安剂量的均值和中位数,并根据年龄进行分层。使用线性回归确定6小时时白消安浓度与AUC之间的关系。对38例患者的39个疗程的白消安进行了评估。在34个疗程(87%)中需要改变初始白消安剂量以达到目标AUC。大多数1至5岁的儿童需要增加剂量,而大多数5岁以上的儿童需要减少剂量。肥胖对白消安剂量需求没有显著影响。6小时时的白消安浓度仅微弱地预测了所达到的AUC(r² = 0.496;P = 0.001)。基于这些发现,我们建议根据患者年龄和实际体重分配初始白消安剂量。我们还建议使用四样本(1小时、1.5小时、4小时和6小时)有限采样技术为儿童计算白消安AUC。

相似文献

1
Retrospective appraisal of busulfan dose adjustment in children.儿童白消安剂量调整的回顾性评估
Bone Marrow Transplant. 2000 Dec;26(11):1143-7. doi: 10.1038/sj.bmt.1702700.
2
An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children.一种用于儿童骨髓移植中个体化白消安给药的改进有限采样方法。
Bone Marrow Transplant. 1997 Sep;20(5):347-54. doi: 10.1038/sj.bmt.1700891.
3
Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation.接受静脉注射白消安进行异基因造血干细胞移植的婴幼儿的药代动力学特征及临床结局
Biol Blood Marrow Transplant. 2007 Mar;13(3):307-14. doi: 10.1016/j.bbmt.2006.10.026.
4
Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation.静脉注射白消安试验剂量的药代动力学指导剂量调整,以在接受造血干细胞移植的低强度预处理方案的儿童中实现每日单次静脉注射白消安的最佳曲线下面积。
Biol Blood Marrow Transplant. 2006 Apr;12(4):472-9. doi: 10.1016/j.bbmt.2005.12.028.
5
Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation.接受异基因干细胞移植的晚期血液系统恶性肿瘤患儿静脉注射白消安的药代动力学及个体化剂量调整
Biol Blood Marrow Transplant. 2004 Nov;10(11):805-12. doi: 10.1016/j.bbmt.2004.07.010.
6
Determination of area under the whole blood concentration versus time curve after first intravenous cyclosporine dose in children undergoing hematopoietic stem cell transplant: limited sampling strategies.造血干细胞移植患儿首次静脉注射环孢素后全血浓度-时间曲线下面积的测定:有限采样策略
Ther Drug Monit. 2008 Aug;30(4):434-8. doi: 10.1097/FTD.0b013e318180c662.
7
Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity.儿童干细胞移植前静脉注射白消安:与早期临床结局和毒性相关的药代动力学研究
Bone Marrow Transplant. 2005 Jan;35(1):17-23. doi: 10.1038/sj.bmt.1704707.
8
Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.采用白消安剂量方案的试验剂量和贝叶斯药代动力学个体化,改善儿科骨髓移植受者的临床结局。
Bone Marrow Transplant. 2001 Oct;28(8):743-51. doi: 10.1038/sj.bmt.1703207.
9
Association of busulfan area under the curve with veno-occlusive disease following BMT.白消安曲线下面积与骨髓移植后静脉闭塞性疾病的关联。
Bone Marrow Transplant. 1996 Feb;17(2):225-30.
10
Once-daily intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics and early clinical outcomes.儿童干细胞移植前每日一次静脉注射白消安:药代动力学及早期临床结果研究
Anticancer Drugs. 2006 Oct;17(9):1099-105. doi: 10.1097/01.cad.0000231482.15277.48.

引用本文的文献

1
Nutritional status, body composition and chemotherapy dosing in children and young people with cancer: a systematic review by the SIOP nutrition network.癌症患儿及青少年的营养状况、身体组成与化疗剂量:国际小儿肿瘤学会营养网络的系统评价
Br J Cancer. 2025 Jun 26. doi: 10.1038/s41416-025-03023-3.
2
Effect of body mass in children with hematologic malignancies undergoing allogeneic bone marrow transplantation.儿童血液恶性肿瘤患者接受异基因骨髓移植时的体重影响。
Blood. 2014 May 29;123(22):3504-11. doi: 10.1182/blood-2013-03-490334. Epub 2014 Apr 7.
3
Pharmacokinetics and drug dosing in obese children.
肥胖儿童的药代动力学与药物剂量
J Pediatr Pharmacol Ther. 2010 Apr;15(2):94-109.